TSHA

Over the past six months, Taysha Gene Therapies' stock price has been influenced by several corporate and clinical developments. The stock closed at $4.49 on October 9, 2026, and has experienced a 10.2% loss over the past 12 months. Key events impacting the stock in the past six months include: Taysha Gene Therapies announced inducement grants under Nasdaq Listing Rule 5635(c)(4) on October 2, 2026, and September 4, 2026. On August 11, 2026, the company reported its Second Quarter 2026 Financial Results, which indicated widening losses but an extended cash runway, associated with a -4.04% stock movement. RA Capital reported a 9.99% stake in TSHA on August 14, 2026, and Morgan Stanley disclosed a 5.1% stake on August 13, 2026. On June 24, 2026, Taysha Gene Therapies priced a 32.5 million-share offering, generating $187 million in net proceeds, and filed for a $200 million common stock and pre-funded warrants offering, associated with a -10.52% stock movement. News regarding TSHA-102 for Rett syndrome showing a 100% response rate and plans for a Biologics License Application (BLA) was released on June 22, 2026.